China Universal Asset Management Co. Ltd. acquired a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 28,906 shares of the company's stock, valued at approximately $359,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Stifel Financial Corp acquired a new position in shares of Indivior during the 3rd quarter worth about $100,000. Melqart Asset Management UK Ltd bought a new stake in shares of Indivior in the 3rd quarter valued at $132,000. Jane Street Group LLC acquired a new stake in Indivior during the 3rd quarter worth $180,000. Public Employees Retirement System of Ohio bought a new position in shares of Indivior during the 3rd quarter valued at about $294,000. Finally, Verition Fund Management LLC acquired a new position in shares of Indivior in the 3rd quarter valued at approximately $375,000. Institutional investors own 60.33% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on INDV shares. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw began coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target for the company. Craig Hallum dropped their price objective on Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, October 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $16.00 price target (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th.
View Our Latest Stock Analysis on Indivior
Indivior Price Performance
Indivior stock traded down $0.37 during mid-day trading on Thursday, hitting $10.65. 1,103,045 shares of the company's stock traded hands, compared to its average volume of 1,132,109. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $23.22. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -266.18 and a beta of 0.74. The firm has a 50 day simple moving average of $11.81 and a two-hundred day simple moving average of $11.06.
About Indivior
(
Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
